Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 16

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 16
---
 between us and Fortress. |

Risks Relating to this Offering

| ● | You will experience immediate dilution in the book value per share of the common stock purchased in the offering. |

| ● | If you purchase our securities in this offering, you may experience future dilution as a result of future equity offerings or other equity issuances. |

| ● | A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price for our common stock. |

| ● | We have broad discretion to determine how to use the funds raised in this offering and may use them in ways that may not enhance our operating results or the price of our common stock. |

| ● | There is no public market for the Warrants and pre-funded warrants being offered in this offering. |

| ● | The holders of Warrants and pre-funded warrants purchased in this offering will have no rights as common stockholders until such holders exercise their Warrants and pre-funded warrants and acquire shares of our common stock, except as set forth in the Warrants and pre-funded warrants. |

| ● | The Warrants are speculative in nature. |

| ● | The Warrants are not exercisable until stockholder approval. |

| ● | The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future. |

| ● | This is a “best efforts” offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans. |

11

THE OFFERING

| Securities we are offering                        |   | 495,000 shares of common stock and accompanying Series C-1 Warrants to purchase up to 495,000 shares of common stock and Series C-2 Warrants to purchase up to 495,000 shares of common stock, pre-funded warrants to purchase 2,162,807 shares of common stock and accompanying Series C-1 Warrants to purchase up to 2,162,807 shares of common stock and Series C-2 Warrants to purchase up to 2,162,807 shares of common stock. The shares of common stock, or pre-funded warrants, and in each case the accompanying Series C-1 Warrants and Series C-2 Warrants will be separately transferable immediately upon issuance, but the shares of common stock, or pre-funded warrants, and in each case the accompanying Warrants will be